Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCD versus CVD for first relapse or primary refractory multiple myeloma
2012-001320-36Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jun 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carfilzomib, bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by University of Leeds. Primary endpoints: Very good partial response rate at 24 weeks and Progression-free survival. Started Jun 2012; status: completed.
02
Drugs
carfilzomibbortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-001320-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001320-36.